SecBot SecBot
SECBOTREPLAY Home › Report › STOK

STOK · Stoke Therapeutics completed enrollment of 162 patients into the Phase…

Stoke Therapeutics, Inc. · 8-K filed Jun 30, 2026 at 08:02 ET

At the news

BULLISHIMPACT 6/10

8-K filed Jun 30, 2026 at 08:02 ET

Stoke Therapeutics completed enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, ahead of a Phase 3 data readout anticipated in Q3 2027 and a rolling NDA submission expected to begin in Q1 2027. This de-risks the pivotal trial timeline and sets up a potential U.S. launch by early 2028, though no efficacy or safety data have been released yet.

  • Enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen completed across U.S., U.K., and Japan.
  • No patients have discontinued treatment in the study.
  • Phase 3 data readout anticipated in Q3 2027; rolling NDA submission to FDA to begin Q1 2027 and complete H2 2027.
  • Approximately 50 of 162 patients are through 28 weeks (primary endpoint of change in major motor seizure frequency).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access